Simulation of the Effects of the Economic Crisis and Response Policies on Children in West and Central Africa: The Case of Burkina Faso

Author(s):  
Lacina Balma ◽  
John Cockburn ◽  
Ismael Fofana ◽  
Samuel Tambi Kabore ◽  
Luca Tiberti
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Malewe Kolou ◽  
Armel Poda ◽  
Zelica Diallo ◽  
Esther Konou ◽  
Tatiana Dokpomiwa ◽  
...  

Abstract Background The presence of the human leukocyte antigen HLA-B*57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B*57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa. Methods A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d’Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B*57:01 in adults with HIV-1. The presence of HLA-B*57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country. Results A total of 4016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38–52. We included 500 (12.4%) patients in Burkina-Faso, 1453 (36.2%) in Côte d’Ivoire, 951 (23.7%) in Gabon, and 1112 (27.7%) in Togo. The overall HLA-B*57:01 prevalence was 0.1% [95% CI: 0.0–0.2%]. The prevalence of HLA-B*57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases. Conclusions HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing for abacavir use in this region.


Subject Prospects for West and Central Africa in 2016. Significance Around a dozen presidential, legislative and municipal elections scheduled for next year portend a disruptive and, in some cases, potentially unstable period. In Ghana, pre-election spending will test official commitment to the country's IMF bailout terms. Elsewhere -- notably Burkina Faso, Guinea and the Central African Republic (CAR) -- political campaigning could magnify long-held internecine grievances, straining the social fabric.


2018 ◽  
pp. 15-27
Author(s):  
Maggie Dwyer

This chapter details the book’s research design. The study takes two distinct but complementary approaches to examining mutinies. One is a dataset that documents the occurrence of mutinies in West and Central Africa from 1960 to 2014. The other approach involves in-depth case studies of mutinies in Sierra Leone, The Gambia, and Burkina Faso, which include extensive interviews with mutineers and others knowledgeable about the revolts. This chapter will also expand on the definition of mutiny used in the research and show how it differs from a coup d’état.


2021 ◽  
Author(s):  
Malewe KOLOU ◽  
Armel PODA ◽  
Zellica DIALLO ◽  
Esther KONOU ◽  
Tatiana DOKPOMIWA ◽  
...  

Abstract Background: The presence of the human leukocyte antigen HLA-B*57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B*57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa. Methods: A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d’Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B*5701 in adults with HIV-1. The presence of HLA-B*57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country. Results: A total of 4,016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38-52. We included 500 (12.4%) patients in Burkina-Faso, 1,453 (36.2%) in Côte d’Ivoire, 951 (23.7%) in Gabon, and 1,112 (27.7%) in Togo. The overall HLA-B*57:01 prevalence was 0.1% [95% CI: 0.0–0.2%]. The prevalence of HLA-B*57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases.Conclusions: HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing in this region.


Sign in / Sign up

Export Citation Format

Share Document